we pursue class action and individual cases in a variety of practice areas


Case Name: In re: Niaspan Antitrust Litigation

Docket No.: 2:13-md-02460


filed:April 15, 2013

court:U.S. District Court, Eastern District of Pennsylvania

The Niaspan case was filed on April 15, 2013 and is now consolidated in the Eastern District of Pennsylvania. This case is a proposed class action alleging defendants entered into anticompetitive “pay for delay” patent settlement agreements for the blockbuster drug Niaspan. Niaspan is a once-a-day prescription formulation of extended release niacin used for treating mixed lipid disorders.

Plaintiffs allege that the brand-name drug manufacturer used its monopoly profits to pay-off potential competitors to refrain from introducing less expensive generic equivalents of the drug for up to eight years, causing consumers and health plans to pay hundreds of millions in overcharges.